Skip to main content
OpenTrials
Completed

NCT Number: NCT01045291

Pacing for Heart Failure With Preserved Ejection Fraction

The purpose of this research study is to evaluate the safety of a new pacing method (Fusion Pacing) for heart failure patients with an ejection fraction (EF) greater than 50% over a period of 4 months, and determine the effects on different measures of heart failure. This new pacing method may allow the heart to pump more efficiently. Participation in this study will last approximately 8 months.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Heart Failure Cardiovascular Diseases Heart Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Aalst, Belgium

Loading trial locations.

About this study

Patients with an EF greater than 50% and a regional mechanical delay of >= 65ms (an indication of mechanical dyssynchrony) will receive an implantable cardioverter defibrillator (ICD) with a special pacing feature. When the feature is active, the device wil pace the left ventricle to target improved pump efficiency. Patients will have the feature active for 4 months and inactive for 4 months. The order will be randomized and the patient will not know whether the pacing is active or not. Echocardiography, biomarkers, exercise testing, quality of life (QOL) testing and device information will be used to compare the patient's status while the feature is active vs. inactive.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients with quantitative ejection fraction (EF) of greater than 50 percent
  • Patients with active heart failure (symptomatic American Heart Association/American College of Cardiology stage C) despite optimal medications
  • Patients greater than 18 years of age
  • Patients willing and able to give informed consent
  • Patients available for appropriate follow-up times for the length of study
  • Patients able to complete cardiopulmonary exercise (CPX) testing
  • Patients expected lifespan is greater than 12 months beyond study enrollment
  • Patients with a regional mechanical delay (RMD) (septal-lateral) greater than 65 milliseconds

Exclusion criteria

  • Patients who have undergone cardiac surgery 60 days prior to enrollment
  • Patients who have had a myocardial infarction 90 days prior to enrollment
  • Patients with hemodynamically significant uncorrected cardiac valvular disease
  • Patients with active myocarditis and amyloidosis (if documented)
  • Patients with a permanent pacemaker
  • Patients with creatinine greater than 2 milligrams per milliliter or estimated glomerular filtration rate (eGFR) less than 30 to 50 milliliters per hour
  • Patients with permanent or chronic sustained atrial fibrillation (fibrillation lasting 7 days or more at a time)
  • Patients with a PR interval greater than 250 milliseconds
  • Patients with severe chronic obstructive pulmonary disease
  • Patients with high risk coronary artery disease
  • Patients who are or expect to become pregnant during this study
  • Patients enrolled in concurrent studies which could confound the results of this study
  • Patients with hypertrophic cardiomyopathy (obstructive or non-obstructive)
  • Patients with infiltrative disease or restrictive cardiomyopathy
  • Patients with indication for percutaneous coronary intervention (PCI) at enrollment

Treatment and study plan

Cardiac Resynchronization Therapy-Defibrillator (CRT-D)

Device

Market approved InSync Sentry™ model 7298, dual chamber Implantable Cardioverter Defibrillator (ICD) with Cardiac Resynchronization Therapy (CRT) including sequential biventricular pacing and OptiVol® fluid monitoring or market approved InSync Maximo™ model 7304 dual chamber ICD with CRT including sequential biventricular pacing.

Other names: Fusion Pacing Investigational Software, Fusion Pacing is an algorithm that is downloaded for use in InSync Sentry™ or InSync Maximo™ devices.

Primary outcomes

  1. Number of adverse events while the Fusion Pacing download is active vs. inactive.

    Time frame: From baseline to 4-month follow-up visit, and 4-month follow-up visit to 8-month follow-up visit

  2. Percentage of time the Fusion Pacing is active throughout a four-month follow-up period.

    Time frame: From baseline to 4-month follow-up visit, and 4-month follow-up visit to 8-month follow-up visit

Secondary outcomes

  1. Change in Minnesota Living with Heart Failure Questionnaire score.

    Time frame: From baseline to 4-month follow-up visit, and 4-month follow-up visit to 8-month follow-up visit

  2. Change in peak VO2 during Cardio-pulmonary Exercise Testing (CPX).

    Time frame: From baseline to 4-month follow-up visit, and 4-month follow-up visit to 8-month follow-up visit

  3. Change in echocardiography measures: E/E', Ejection Fraction, LV EDV.

    Time frame: From baseline to 4-month follow-up visit, and 4-month follow-up visit to 8-month follow-up visit

  4. Change in NT-proBNP.

    Time frame: From baseline to 4-month follow-up visit, and 4-month follow-up visit to 8-month follow-up visit

Sponsors and collaborators

Lead sponsor

Medtronic Cardiac Rhythm and Heart Failure

Industry

Registry information

Acronym: HFpEF

Important dates

Study start
2010
Primary completion
2013
Study completion
2013
First posted
Jan 11, 2010
Registry last updated
May 30, 2013

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.